Overview of Dolfort-De

What is Dolfort-De?

Property	Description
Active Ingredients	Ketoprofen, Acetaminophen (Paracetamol)
Form	Oral Dosage Form (e.g., Tablet)
Pharmacological Class	NSAID and Miscellaneous Analgesic
General Purpose	Pain Relief, Fever Reduction, Inflammation Control
Origin	Synthetic

Dolfort-De is a fixed-dose combination medicinal product, strategically formulated for oral administration, containing the synthetic active agents Ketoprofen and Acetaminophen (Paracetamol). This formulation functions as an analgesic, antipyretic, and anti-inflammatory agent, designed to manage pain, fever, and swelling concurrently.

Defining Dolfort-De: Class and Fixed-Dose Combination

Dolfort-De is categorized as a fixed-dose combination of an NSAID (Nonsteroidal Anti-inflammatory Drug) and a non-opioid analgesic, engineered for comprehensive pain and inflammation management. The strategic pairing of these agents from different pharmacological classes—Ketoprofen and Acetaminophen—into a single oral dosage form provides relief for moderately severe acute pain symptoms, such as post-operative discomfort. The resulting product is designed to achieve a synergistic effect, offering pain relief (analgesia) and control over fever (antipyresis) through the combined action of its ingredients.

The Composition: Ketoprofen and Acetaminophen (Paracetamol)

Both Ketoprofen and Acetaminophen are synthetic organic compounds. Ketoprofen is classified as a propionic acid derivative and belongs to the NSAID class, responsible for the drug's primary anti-inflammatory actions. Acetaminophen (Paracetamol) is a miscellaneous analgesic and antipyretic agent.

The NSAID component’s anti-inflammatory action involves the inhibition of cyclooxygenase enzymes. This mechanism works to reduce the chemical messengers that cause swelling and pain. The medication's oral dosage form ensures the synchronized delivery of these two pharmacologically distinct substances.

Regulatory References

What side effects are possible with Dolfort-De?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety constraints of the combined active ingredients—Ketoprofen (an NSAID) and Acetaminophen (Paracetamol)—based strictly on government regulatory sources.

Adverse Reaction Categories

Adverse effects are classified by the affected System Organ Class (SOC) and by official frequency (e.g., Common, Rare), as listed in regulatory labeling.

System Organ Class (SOC)	Frequency Classification	Notable Reactions (Official Labeling)
Gastrointestinal Disorders	Very Common o Rare	Dyspepsia, Nausea, Abdominal Pain, Vomiting, Constipation, Diarrhea, Gastritis
Nervous System Disorders	Common o Rare	Headache, Dizziness, Somnolence, Confusion, Migraine, Paresthesia
Renal and Urinary Disorders	Common o Rare	Impairment of renal function, Edema, Renal Failure, Hematuria
Skin and Subcutaneous Tissue	Common o Rare	Rash, Pruritus, Urticaria, Photosensitivity Reactions, Blisters

Documented Serious Adverse Reactions

Regulatory documents explicitly list severe and potentially fatal reactions associated with the components:

Serious Gastrointestinal Events: Risk of ulceration, bleeding, and perforation of the stomach or intestines, which can occur without warning symptoms at any time during treatment.
Serious Cardiovascular Thrombotic Events: Increased risk of Myocardial Infarction (heart attack) and Stroke, which can be fatal. This risk is officially noted as dose-dependent and potentially higher with longer duration of use.
Severe Cutaneous Adverse Reactions (SCARs): Including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP).
Hepatic Injury: Severe Liver Damage and Acute Liver Failure, particularly associated with the Acetaminophen component.

Population-Specific Safety Constraints

Older Adults: Increased risk of serious adverse reactions from NSAIDs, especially gastrointestinal bleeding and renal problems.
Severe Hepatic Impairment: The Acetaminophen component is officially contraindicated in patients with severe active liver disease.
Pregnancy (Third Trimester): The NSAID component is contraindicated due to the risk of fetal cardiopulmonary toxicity and renal dysfunction.
Cardiac Surgery Restriction: The NSAID component should not be used right before or after Coronary Artery Bypass Graft (CABG) surgery.

Overdose and Emergency Response

The official overdose profile for Dolfort-De, a fixed-dose combination of an NSAID (Ketoprofen) and Acetaminophen, is defined by the toxicological risks associated with both active components. Overdose may present with a variety of clinical manifestations, including initial gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, along with central nervous system effects such as drowsiness, lethargy, confusion, and headache. Tinnitus and excessive sweating (diaphoresis) are also documented signs.

Overdose scenarios carry a risk of severe or life-threatening outcomes. Documented complications include Fatal Hepatic Necrosis (severe liver failure) from the Acetaminophen component and major events from the NSAID component, such as Acute Renal Failure and Gastrointestinal Bleeding or perforation. Severe neurological events like seizures and coma are also officially noted.

Immediate medical attention is required upon any known or suspected overdose. Due to the risk of delayed, progressive liver toxicity, regulatory authorities mandate that medical help must be sought immediately, even if the individual appears to have no symptoms. Management is primarily symptomatic and supportive treatment. While the Ketoprofen component has no specific antidote, N-acetylcysteine is the specific antidote for Acetaminophen overdose and is critical for minimizing hepatic injury if administered promptly. Hospital monitoring, including liver function and drug concentration tests, is required.

Therapeutic Uses of Dolfort-De

What Dolfort-De Treats: Main Uses and Benefits

The fixed-dose combination of an NSAID (Ketoprofen) and Acetaminophen (Paracetamol) is applied in addressing simultaneous pain, inflammation, and fever. It is relevant in clinical settings marked by heightened patient distress and is commonly used when short-term symptomatic assistance is needed. The combination of a non-opioid analgesic like Paracetamol and an NSAID generally may be part of symptomatic management in strategies for acute pain management.

Key Therapeutic Domains

This medication is primarily applied to address moderate to severe acute pain states that appear suddenly or intensify over a short period. It offers symptomatic support that helps ease the overall burden of pain during initial recovery, contributes to easing the overall symptom load when symptoms are more noticeable. Relevant use cases include discomfort following surgical procedures, musculoskeletal strain, symptoms related to inflammatory or irritative states, and recurrent episodic manifestations.

It is applied in scenarios where additional management of discomfort is required, especially when symptoms cluster into patterns requiring supportive management.

Dolfort-De is relevant across conditions characterized by episodic or fluctuating symptom patterns where pain is accompanied by signs of inflammation (swelling or redness). This medication helps address symptom clusters that occur together, offering relief that may help patients cope more steadily with symptom fluctuations during challenging symptomatic phases.

Quick Fact: Relief for Acute Symptom Clusters Dolfort-De supports the patient during difficult episodes by assisting with easing the discomfort when multiple symptoms, such as pain, fever, and inflammation, occur together and interfere with daily functioning.

Eligibility and Restrictions for Use

The eligibility for Dolfort-De is strictly defined by the regulatory warnings associated with its active components, Ketoprofen (an NSAID) and Acetaminophen (Paracetamol).

Populations Who Must Not Use (Contraindicated)

Category	Contraindication Rule
Allergy	History of Aspirin-sensitive asthma or severe allergic reaction to any NSAID (Nonsteroidal Anti-inflammatory Drug).
Surgery	For pain relief right before or after Coronary Artery Bypass Graft (CABG) surgery (NSAID component restriction).
Pregnancy	Women who are 30 weeks pregnant or later (third trimester).
Organ Function	Patients with severe hepatic failure or severe renal impairment.

Age and Condition-Based Restrictions

Pediatric Use: Safety and efficacy are not established or recommended for children and adolescents, typically under 16 years of age.
Older Adults: Use requires vigilance and caution due to an increased risk of serious gastrointestinal and kidney-related adverse events.
Conditional Use: Patients with a history of GI bleeding or ulceration, congestive heart failure, or hypertension must use the medicine with caution and close monitoring, as defined by regulatory labeling. Use during lactation requires a benefit/risk assessment.

What should I know about interactions with other medicines?

Drug Interactions

Dolfort-De, as a nonsteroidal anti-inflammatory drug (NSAID), is associated with several established drug-drug interactions that can affect both the safety and effectiveness of concomitant medicines. These interactions primarily stem from the inhibition of prostaglandin synthesis and effects on renal function and blood coagulation.

Interacting Product Category	Potential Effect	Interaction Type
Anticoagulants/Antiplatelets (e.g., warfarin, dabigatran, aspirin)	Significantly increased risk of bleeding, particularly serious gastrointestinal hemorrhage.	Pharmacodynamic
ACE Inhibitors/ARBs/Diuretics (e.g., lisinopril, losartan, furosemide)	Decreased antihypertensive/diuretic efficacy and increased risk of worsening hypertension and acute kidney injury.	Pharmacodynamic/Renal
Lithium	May increase serum lithium levels, leading to toxicity, due to reduced renal clearance.	Pharmacokinetic
Methotrexate	May increase plasma methotrexate levels and risk of toxicity, especially at high doses, due to reduced excretion.	Pharmacokinetic
Corticosteroids (e.g., prednisone)	Greatly increased risk of serious gastrointestinal adverse events, including ulceration and bleeding.	Pharmacodynamic

Combination with other NSAIDs should be avoided due to an additive risk of adverse effects, including gastrointestinal and renal toxicity. Additionally, use is restricted immediately before and after coronary artery bypass graft (CABG) surgery due to an elevated risk of cardiovascular thrombotic events. The daily use of alcohol and tobacco is also noted in regulatory documentation to increase the risk of stomach bleeding when combined with this product, necessitating restriction.

Mechanism of Action

Dolfort-De is a highly selective inhibitor of the cathepsin K (CatK) enzyme. CatK is a cysteine protease predominantly expressed within osteoclasts, the cells responsible for bone resorption. The primary function of this enzyme involves the enzymatic hydrolysis of the organic bone matrix components, specifically Type I collagen, during the resorption process.

Dolfort-De acts by binding to and inhibiting the catalytic site of CatK. This molecular interaction decreases the CatK-mediated cleavage of the organic bone matrix. The resulting reduction in CatK activity causes a sustained decrease in collagen breakdown, thereby modulating the dynamic equilibrium between bone resorption and bone formation. This mechanism focuses specifically on the inhibition of CatK activity, which is distinct from the molecular targets of non-selective inhibitors.

Dosage and Administration Information

How to Use Dolfort-De

Dolfort-De is a fixed-dose combination product containing Ketoprofen and Acetaminophen (Paracetamol) and is authorized for oral administration as a tablet. The administration regimen is based on a fixed interval schedule, structured to ensure optimal dosing while remaining within established parameters for both active components.

The standard administration involves taking one tablet (unit dose: Ketoprofen 100 mg / Acetaminophen 1000 mg) up to three times daily. To maintain consistency and adhere to maximum thresholds, a minimum interval of eight hours must be observed between doses. The total intake must not exceed three tablets in any 24-hour period. This maximum dose limit is a core constraint of the protocol for the product's short-term use.

The medication is intended solely for short-term administration to address acute symptomatic needs, and it is not intended for chronic treatment. The tablet should be swallowed whole with a full glass of water, and standard guidelines suggest administration with food or milk to aid the gastrointestinal tolerability of the NSAID component.

For special populations, such as older adults, product guidelines emphasize using the lowest effective dose for the shortest duration possible. If a dose is missed, established protocols advise the patient to skip the missed dose and resume the schedule with the next dose at the regular time, without doubling up. These protocols establish the standardized procedural structure for using the medicine.

Recent Clinical Evidence

Dolfort-De: Recent Clinical Evidence

This overview provides a neutral summary of the type of research conducted on the fixed-dose combination of Ketoprofen and Acetaminophen (Dolfort-De). The findings describe group patterns observed in studies, not individual predictions or clinical recommendations.

Evidence for Use in Acute Postoperative Pain

The clinical evaluation primarily relies on randomized controlled trials (RCTs) and meta-analyses that examined the combination in standardized acute pain models, such as discomfort following surgical procedures. Research focused on outcomes related to physical discomfort, tracking the magnitude of pain reduction and the time until relief was reported. Studies monitored the use of supplemental rescue medication and compared measurements against those recorded for placebo or the individual active ingredients. However, the generalizability of findings to all types of acute surgery is not fully established, as these specialized surgical models are used for comparison.

Evidence for Use in General Acute Pain Conditions

Research explored this combination within systematic reviews covering various moderate-to-severe pain states, including musculoskeletal discomfort. Studies monitored outcomes reflecting daily functioning and described patterns related to pain intensity changes. While these comparisons against monotherapy have shown mixed results, the research explored this approach within trials assessing short-term or episodic symptom patterns. Comparative evidence is lacking when assessing this specific fixed-dose combination against other approved combination analgesics.

Short-Term Focus: Study Duration and Follow-up

The research primarily focused on short-term symptom changes, with many pivotal trials designed for single-dose observation, lasting only 4 to 10 hours. Other studies involved multi-day periods, often up to seven days. Follow-up durations were limited, and sufficient information about long-term outcomes or the durability of observed symptom changes is not yet available.

Evidence in Defined Patient Groups (Special Populations)

Most core research was evaluated in adult populations with no significant comorbidities. Data for certain groups remain insufficient. Few specific trials explored the combination in older adults or in patients with specific chronic health issues. Research on the combination’s ingredients in pediatric patients following surgery exists, but subgroup findings are uncertain.

Evidence Gaps and Areas of Ongoing Research

Research limitations include the fact that the evidence quality varies across studies, and many results apply only to the standardized pain models used. Long-term effects are not fully established, and comparative evidence against other combination treatments is lacking. Data for certain vulnerable populations (such as pregnant patients or those with specific organ dysfunction) remain insufficient.

Key Studies & References Acetaminophen (Paracetamol) (Compound Summary) - PubChem

Frequently Asked Questions (FAQ)

Common questions about Dolfort-De (FAQ)

Q: How quickly should I expect Dolfort-De to start working?

Studies on the components of Dolfort-De indicate a relatively rapid onset of action. Regulatory documents suggest that the component Ketoprofen has a rapid onset, with studies noting pain relief can begin for some patients within 30 minutes of administration. Clinical research on the fixed-dose combination product also suggests a quick start to its analgesic effects.

Q: How long does the effect of one dose of Dolfort-De typically last?

The administration regimen for Dolfort-De is structured around a minimum interval of eight hours between doses. This regulatory constraint helps structure the dosing regimen. Clinical studies often monitor the product's effects for a duration that supports the minimum eight-hour dosing interval.

Q: What kind of research backs up the use of Dolfort-De for nerve pain?

The available clinical evidence focuses primarily on its use for managing acute postoperative pain and various general moderate-to-severe pain states, including discomfort in the muscles and skeleton. Specific effectiveness for neuropathic pain is not the main focus area detailed in the current regulatory evidence overview.

Q: Is it true that Dolfort-De is sometimes used for back spasms?

The combination is studied for general musculoskeletal discomfort and moderate-to-severe pain states. However, the specific term 'back spasms' is not detailed in the clinical evidence overview for the combination product.

Q: What is the longest period someone usually takes Dolfort-De for?

Official prescribing information states that this medication is intended solely for short-term administration. It is designed to address acute, temporary symptoms and is explicitly not approved for chronic or long-term treatment.

Q: What happens if I miss a scheduled dose of Dolfort-De?

The official protocol advises skipping the missed dose. Patients should then resume the schedule with the next dose at the regular time, avoiding taking extra to compensate.

Q: Why is it important to check for drug interactions with Dolfort-De?

Regulatory warnings highlight the importance of checking for interactions because combining the medication with certain drugs, such as blood thinners or corticosteroids, can significantly increase the risk of serious adverse events like major bleeding or acute kidney injury.

Q: What conditions is Dolfort-De most commonly prescribed for?

Clinical evaluation has focused heavily on standardized acute pain models, making the management of acute postoperative pain a key area of use. Studies primarily rely on evidence showing its effectiveness in providing relief for moderate-to-severe pain after surgical procedures.

Q: Are there different strengths of Dolfort-De available?

The standard administration regimen is based on a fixed unit dose of Ketoprofen 100 mg and Acetaminophen 1000 mg per tablet. Regulatory information on the fixed-dose combination product specifies only this single strength.

Q: Can Dolfort-De cause changes in mood or behavior?

The components of the medication have been associated with Nervous System Disorders that may include adverse reactions like confusion. Official safety information for the NSAID component notes that, in rare cases, mental or mood changes have also been reported.

Q: What should I do if I experience an unusual side effect while taking Dolfort-De?

Official safety information requires patients to be alert for signs of a serious adverse reaction, such as evidence of bleeding, severe allergic response, chest pain, or difficulty breathing. Experiencing these warning signs indicates the need to seek prompt medical attention.

Q: How does Dolfort-De compare to similar drugs in terms of side effect profile?

Official clinical trial summaries note a gap in available research for direct comparisons. Comparative evidence is lacking when assessing this specific fixed-dose combination against other fully approved combination analgesics.

Q: What is the primary mechanism by which Dolfort-De relieves symptoms?

Dolfort-De is effective because it combines two agents with different actions. The Ketoprofen component (an NSAID) helps reduce pain, inflammation, and fever, while the Acetaminophen component is added for further general pain relief and fever control.

Q: Can Dolfort-De be crushed or split?

Official instructions for administration state that the tablet should be swallowed whole with a full glass of water. This is necessary to ensure the proper and synchronized delivery of the fixed-dose combination.

Q: Is it okay to stop taking Dolfort-De suddenly, or should I taper off?

Since the medication is prescribed for short-term administration to treat acute symptoms, a specific tapering schedule is generally not required upon discontinuation. Decisions regarding stopping the medication should be made in consultation with a healthcare provider.

Q: Why would a doctor switch me from another drug to Dolfort-De?

The unique feature of Dolfort-De is the strategic combination of two distinct pain relievers into a single tablet. This combination is designed to achieve a synergistic effect, meaning it may offer more complete pain relief than either individual component could provide on its own.

Q: Can lifestyle factors like diet or exercise impact how well Dolfort-De works?

Regulatory information specifically warns that the use of alcohol and tobacco can increase the risk of stomach bleeding when combined with this product. Additionally, taking the tablet with food or milk is often suggested to help reduce gastrointestinal side effects.

Q: Does Dolfort-De interact with herbal supplements?

While the product label does not list specific herbal supplements as contraindications, the active components are known to potentially interact with various herbal supplements and vitamins. Patients typically review their full list of medications and supplements with a healthcare provider to check for potential interactions.

Q: Are there any long-term side effects associated with taking Dolfort-De?

Most clinical research focused on short-term symptom changes, and sufficient information about long-term outcomes is not fully established. It is officially noted, however, that the risk of serious cardiovascular events, such as heart attack or stroke, may be higher with a longer duration of use.

Q: Does Dolfort-De affect sleep patterns?

The medication can cause reactions that fall under the category of Nervous System Disorders. These may include somnolence (drowsiness) and, for some patients, difficulty with falling asleep or staying asleep.

Q: What makes Dolfort-De different from over-the-counter cold remedies?

Dolfort-De is a fixed-dose combination that provides a prescription-strength dose of both the NSAID Ketoprofen and Acetaminophen. This combination and dosage strength are typically different and higher than what is found in multi-symptom, over-the-counter cold remedies.

Q: What is the general consensus in medical literature about Dolfort-De's effectiveness?

The medical consensus, based on clinical evaluation, describes that the combination is an effective option for providing relief for moderate-to-severe acute pain symptoms. Its use is supported by studies in standardized pain models, such as after surgical procedures, for short-term symptom management.

Q: What are the official clinical trials saying about Dolfort-De?

Official clinical trials primarily rely on randomized controlled trials (RCTs) and meta-analyses conducted in acute pain settings. These studies monitor the magnitude of pain reduction and the time it takes until relief is reported in comparison to placebo or individual components.

Q: Does Dolfort-De have a risk of dependence or addiction?

Dolfort-De is classified as an NSAID and Miscellaneous Analgesic. It is not categorized as an opioid or controlled substance, and regulatory documents do not associate it with risks of dependence or addiction.

How should Dolfort-De be stored and disposed of?

How to Store and Dispose of Dolfort-De

Official regulatory documents define the required conditions for storing this medication to ensure its stability.

Storage and Handling Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, 20^circC to 25^circC (68^circF to 77^circF).
Protection	Keep in the original container, tightly closed, and protect from heat, moisture, and light. Do not freeze.
Child Safety	Must be kept out of the reach and sight of children.

Disposal Instructions

Disposal of unused or expired tablets must comply with local laws and regulations. Do not flush the medicine down the toilet or pour it down a sink. Patients should utilize an authorized medicine take-back program or follow specific guidelines provided by national health authorities for discarding medicine safely.

Dolfort-De